The saga may finally end under new Chief Executive Paul Keel , who according to the Mail on Sunday is in advanced talks with U.S. private equity group TA Associates about a 2 billion pound bidfor the medical division. That’s below the 2.1 billion pounds JPMorgan analysts think it’s worth.
Investors’ bigger gripe will be the slow progress: Smiths’s shares have trailed the Refinitiv Global Industrials Index by 20 percentage points since it announced the separation plans in 2018. The company’s glacial breakup is heading for a lacklustre conclusion. Atos profit warning may tempt bottom-feeders
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: